Search

Displaying results 4961 - 4970 of 8974 in total
  1. Drug

    Cefovecin

    go.drugbank.com/drugs/DB11505
    ExperimentalVet approved

    It is used for the treatment of skin infections caused by Pasturella multocida in cats, and Staphylococcus intermedius/S. canis in dogs. … The presence of low concentrations of antibiotics is related to the development of microbial resistance.

  2. Drug

    Oportuzumab monatox

    go.drugbank.com/drugs/DB05319
    Investigational

    VB4-845 is made by linking a monoclonal antibody fragment to a toxic protein that may kill cancer cells. … VB4-845 is a fusion protein containing humanized scFv specific for the epithelial cell adhesion molecule, Ep-CAM, a tumor cell-associated target highly expressed on carcinoma cells of epithelial origin

  3. Drug

    Nicotinamide Mononucleotide

    go.drugbank.com/drugs/DB03227
    Investigational

    3-Carbamoyl-1-beta-D-ribofuranosyl pyridinium hydroxide-5'phosphate, inner salt.

  4. Drug

    Rumex acetosella pollen

    go.drugbank.com/drugs/DB10359
    Approved

    Rumex acetosella pollen is the pollen of the Rumex acetosella plant. Rumex acetosella pollen is mainly used in allergenic testing.

    Mixtures: Number Four Weed Mixture, Number Two Weed Mixture
  5. Drug

    AAV-AIPL

    go.drugbank.com/drugs/DB17857
    Experimental

    Developed by MeiraGTx, it is being investigated for the treatment of inherited retinal dystrophy due to defects in _AIPL1_ gene.

  6. Drug

    AGS-004

    go.drugbank.com/drugs/DB05742
    Investigational

    A personalized immunotherapy addresses these issues because it is able to capture private viral mutations, providing a matched, complete immune response for each individual HIV patient. … This approach may overcome the weaknesses of other available therapies and therefore could result in a better chance of success for HIV treatment.

  7. Drug

    MVC-COV1901

    go.drugbank.com/drugs/DB15854
    Investigational

    MVC-COV1901 is a vaccine candidate developed and commercialized by Medigen Vaccine Biologics Corporation. The vaccine candidate contains a perfusion form of the SARS-Cov2 recombinant spike protein. … As of September 2020, the vaccine candidate is in Phase 1 clinical trials to assess its safety and immunogenicity (NCT04487210).

  8. Drug

    Firocoxib

    go.drugbank.com/drugs/DB09217
    ExperimentalVet approved

    It currently approved for veterinary use in dogs and horses under the brand names Equioxx and Previcox. Firocoxib was the first COX-2 inhibitor approved by the U.S. … Food and Drug Administration for horses. Firocoxib is not intended or approved for use in human medicine.

  9. Drug

    AAV1-FS344

    go.drugbank.com/drugs/DB17855
    Investigational

    AAV1-FS344 is an investigational gene therapy developed by Milo Biotechnology to deliver follistatin, a potent myostatin inhibitor. … It is being investigated for the treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and inclusion body myositis.[L46742, L46747, L46752]

  10. Drug

    Fusafungine

    go.drugbank.com/drugs/DB08965
    ApprovedWithdrawn

    Fusafungine is an antibiotic from Fusarium lateririum, and is used for the treatment of respiratory infections.